Effects of Interleukin-1 Inhibition on C-Reactive Protein Levels, Endothelial Progenitor Cell Mobilization and Endothelial Function in Patients With Coronary Artery Disease.
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2012
At a glance
- Drugs Rilonacept (Primary)
- Indications Atherosclerosis; Coronary arteriosclerosis
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 20 Apr 2010 Actual number of patients added to 60 as reported by ClinicalTrials.gov.
- 20 Apr 2010 Actual end date added to 1 Apr 2008 as reported by ClinicalTrials.gov.